Status:
ACTIVE_NOT_RECRUITING
Implementation of a New Model of Care for Supporting Long-term Medication Adherence (Phase A)
Lead Sponsor:
University of Geneva, Switzerland
Collaborating Sponsors:
University of Basel
Fundació Sant Joan de Déu
Conditions:
Medication Initiation for Long-term Conditions
Eligibility:
All Genders
18+ years
Brief Summary
The overall objective of the myCare Start-I project is to adapt, implement and evaluate the myCare Start service within the Swiss pharmacy-physician network to enhance medication adherence during the ...
Detailed Description
Phase A: 1. To conduct a contextual analysis of the current Swiss primary care ecosystem as related to pharmacy-physician interprofessional health services for patients with long-term diseases (i.e.,...
Eligibility Criteria
Inclusion
- Phase A: contextual analysis
- Community pharmacists and technicians of 5 participating pharmacies in the French-speaking part of Switzerland and 5 in the German-speaking part of Switzerland
- Primary care physicians working in collaboration or in the neighbourhood of the participating pharmacies
- Patients with long-term treatments, who are a regular patients of the included pharmacies
- International research groups who have implemented NMS within their countries or similar interventions.
Exclusion
- Patients not willing to participate
- Patients that do not speak French or German
- Phase B: hybrid type 2 effectiveness-implementation study
- Patients are eligible for the myCare Start-I phase B study if :
- They are taking part in the myCare Start service
- They have been newly prescribed one or more new long-term medications in accordance with one of the five defined long-term conditions (cardiovascular disease (incl. hypertension and thromboprophylaxis), diabetes, hyperlipidaemia, depression and respiratory illness (asthma, COPD))
- They are 18 years or older
- They have mandatory basic health insurance in Switzerland
- They are able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-/herself).
- They understand language spoken by pharmacy staff and are able to read and understand study documents (ge, fr)
- They are able to understand and willing to consent to the myCare Start study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)
- Exclusion criteria:
- • Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients).
- myCare Start definition of a new medication:
- A new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition.
- Operational definition of a new medication:
- Active ingredient is indicated for one of the five long-term conditions (cardiovascular disease (incl. hypertension and thromboprophylaxis), diabetes, hyperlipidaemia, depression and respiratory illness (asthma, COPD)).
- Patient has never had this active ingredient dispensed before or restarts an active ingredient after a period of interruption of at least 12 months.
- The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)
- Patient has had no change in active ingredient but has an important change in treatment administration, such as:
- Change of galenic form (e.g. two different types on inhalators for asthma/COPD)
- Intensification of dosage regimen (e.g. twice a day instead of once a day)
- The following change is not considered as medication initiation:
- New dosage of already known active ingredient (e.g. dose escalation of antidepressants)
- Simplification of administration mode (e.g. metformin 1000mg 1-0-0 instead of 500mg 1-0-1; change in antihypertensive drug regimen in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)
Key Trial Info
Start Date :
August 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06191835
Start Date
August 30 2023
End Date
June 30 2026
Last Update
April 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Université de Genève
Geneva, Canton of Geneva, Switzerland, 1211
2
University of Basel
Basel, Switzerland, 4056